Drug Trial Radar · NCT05716945
The OPTIMISE Study
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
342
Planned (sponsor's estimate)
Start
Jul 29, 2024
Primary completion
Sep 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Maastricht University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale: The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the preferred method in the past decade. The main advantage of DMEK over previous techniques is a low graft rejection rate (1-2% per year). Despite this, rejection prophylaxis after DMEK follows the same high potency regimen as previous techniques in the first year, and patients are burdened with indefinite immunosuppression. The current project, OPTIMISE, aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. Corticosteroid eye drops are the mainstay of ocular immunomodulatory therapy. Their main side effect is a steroid-induced increase in intraocular pressure (IOP). It manifests in about one-fourth of patients within the first year after surgery and can lead to irreversible optic nerve damage and vision loss. Patients with IOP elevation require additional medications and hospital visits resulting in reduced quality of life and increased costs. The optimal dosing regimen in the first year after DMEK and whether patients may safely stop steroids after one year remains unknown. As a result, protocols in the Netherlands vary considerably from surgeon to surgeon. Patients are potentially over-treated in the short and long-term, resulting in undue burden for the patient and increased costs. Consequently, the Dutch Ophthalmology Society (NOG) identified the optimal short- and long-term immunosuppressive protocol for corneal transplantation as one of its Top 10 knowledge gaps, underscoring relevance for clinical practice. With this work, the investigators expect to address this knowledge gap to the benefit of our patients and society. Objective: The OPTIMISE study aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. The hypothesis of this study is that Fluorometholone 0.1% in the first year and discontinuing medication in the second year is a cost-effective treatment strategy after DMEK. Study design: The design of this study is a randomized, controlled multicentre trial with a duration of 24 months. Study population: The study population will consist of 342 patients aged 21 years or older undergoing DMEK surgery in one eye. Intervention: All patients will receive Descemet's Membrane Endothelial Keratoplasty. Following this procedure, patients will be randomized into the following post-operative regime in two stages: STEP-I (Year 1): Control group: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months. Intervention group: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. STEP-II (Year 2): Control Group: Half the patients in each study arm will use FML 0.1% daily. Intervention Group: Half the patients in each study arm will discontinue steroids. Main study parameters/endpoints: Primary outcomes: Step-I: IOP elevation compared to baseline Step-II: Endothelial cell loss (ECL) in the second year Secondary outcomes are: * Rejection free graft survival. * Patient reported outcome measures. * Incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE) * Structural outcomes including corneal, central macular and retinal nerve fibre layer thicknesses, and optic nerve head imaging.
Conditions
- Pseudophakic Bullous Keratopathy
- Fuchs' Endothelial Dystrophy
- Intraocular Pressure
Interventions
Fluorometholone 0.1% Oph SuspDrug
Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. Year 2: Half the patients in each study arm will use FML 0.1% daily.
Dexamethasone 0.1% ophthalmic suspensionDrug
Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
Stop steroidsOther
Half the patients in each study arm will discontinue steroids.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference of intraocular pressure elevation between the two armsTime frame: Year 1
- Difference of endothelial cell loss (ECL) in the second yearTime frame: Year 2
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Gelre Ziekenhuizen
Apeldoorn, Gelderland, Netherlands · Recruiting
Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands · Recruiting
Maastricht Universitair Medisch Centrum+
Maastricht, Limburg, Netherlands · Recruiting
Amsterdam Universitair Medisch Centrum
Amsterdam, North Holland, Netherlands · Recruiting
Deventer Ziekenhuis
Deventer, Overijssel, Netherlands · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Provincie Groningen, Netherlands · Not yet recruiting
Leiden Universitair Medisch Centrum
Leiden, South Holland, Netherlands · Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, Utrecht, Netherlands · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.